EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Breaking the sound barrier: global monoclonal antibody pharmacoequity

Huub C Gelderblom, Glenda Gray, Brian Kelley

Frontiers in Pediatrics · 23.06.2026 · 14

DOI: 10.3389/fped.2026.1845146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pediatrics, online erschienen am 23.06.2026. Verfasst von Huub C Gelderblom und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutch Cancer Center, Vaccine and Infectious Disease Division, Seattle, WA, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies represent one of biomedicine's greatest successes, yet global access remains profoundly inequitable, with low- and middle-income countries bearing the brunt of limited access. This perspective proposes that long-acting infectious disease mAbs, starting with WHO-recommended nirsevimab for RSV prevention, could catalyze transformation by connecting with existing WHO Essential Medicines List mAbs. Picture two static half-circles: WHO Essential Medicines List mAbs with proven value but limited access, and infectious disease prevention mAbs with transformative potential. Connected, they form a complete wheel capable of rolling toward the aspirations of global pharmacoequity. HIV antiretroviral therapy demonstrates precedent—costs declined 100-fold through political mobilization, not technological breakthroughs.

Schlagwörter

Stichwörter der Autor:innen

RSV (respiratory syncytial virus) prophylaxisaccess to medicinesbiologicsdisease preventionessential medicinesmonoclonal antibodiespharmacoequityvolume catalyst

Autor:innen und Institutionen

  • Fred Hutch Cancer Center, Vaccine and Infectious Disease Division, Seattle, WA, United States.
  • South African Medical Research Council, Cape Town, South Africa.
  • Infectious Disease and Oncology Research Institute, University of Witwatersrand, Johannesburg, South Africa.
  • BK Biopharma Consulting, LLC, Burlingame, CA, United States.

Zitieren

APA

Gelderblom, H. C., Gray, G., & Kelley, B. (2026). Breaking the sound barrier: global monoclonal antibody pharmacoequity. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1845146

Vancouver

Gelderblom HC, Gray G, Kelley B. Breaking the sound barrier: global monoclonal antibody pharmacoequity. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1845146

BibTeX
@article{Gelderblom2026,
  author = {Gelderblom, Huub C and Gray, Glenda and Kelley, Brian},
  title = {Breaking the sound barrier: global monoclonal antibody pharmacoequity},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1845146}
}
Kostenlos starten →